Table II.
Platinum plasma pharmacokinetic parameters after intraperitoneal (IP) or intravenous (IV) administration of nanoemulsion (NE) formulations and cisplatin in nu/nu mice, (n=3).
| Group | Route | t1/2 (h) | Tmax (h) | Cmax (μg/mL) | Vd (mL/kg) | Cl (mL/h/kg) | MRT (h) | AUClast (h*μg/mL) |
|---|---|---|---|---|---|---|---|---|
| Non-targeted NE | IP | 11 | 3.0 | 5.4 | 1021 | 63 | 15 | 63 |
| EGFR-targeted NE | IP | 15 | 3.0 | 7.3 | 889 | 41 | 22 | 81 |
| Non-targeted NE | IV | 12 | 0.08 | 25 | 804 | 46 | 16 | 82 |
| EGFR-targeted NE | IV | 10 | 0.5 | 20 | 657 | 45 | 14 | 86 |
| Cisplatin (Total – Bound and Unbound) | IV | 9.6 | 0.083 | 6.9 | 6,752 | 485 | 18.6 | 14 |
| Cisplatin (Unbound) | IV | 2.8 | 0.083 | 2.6 | 31,278 | 7,776 | 1.7 | 1.2 |